JSPR Jasper Therapeutics, Inc. - Class A

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

$0.85
As of 10/05/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  09/20/2021
Outstanding shares:  36,580,263
Average volume:  101,711
Market cap:   $29,271,526
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.80
PB ratio:   0.46
PS ratio:   2.65
Return on equity:   -71.13%
Net income %:   -438.21%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy